Market Cap (In USD)
185.52 Million
Revenue (In USD)
18.68 Million
Net Income (In USD)
-6.71 Million
Avg. Volume
169.94 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 10.06-24.0
- PE
- -
- EPS
- -
- Beta Value
- 0.838
- ISIN
- IL0011316309
- CUSIP
- M68830104
- CIK
- 1593984
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ofer Gonen B.Sc.
- Employee Count
- -
- Website
- https://www.mediwound.com
- Ipo Date
- 2014-03-20
- Details
- MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
More Stocks
-
9565GLOE Inc.
9565
-
5599S&J CORPORATION
5599
-
2379DIP Corporation
2379
-
0592
-
WAK
-
FRCBFirst Republic Bank
FRCB
-
HUDL
-
601288